Bradley Hunter, MD. MPH

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Kite Pharma
    Topic:
    CAR T-cell therapy
    Date added:
    06/24/2022
    Date updated:
    09/19/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    BMS
    Topic:
    CAR T-cell therapy
    Date added:
    06/24/2022
    Date updated:
    09/19/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Janssen
    Topic:
    Bispecifics
    Date added:
    06/24/2022
    Date updated:
    09/19/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    ADC Therapeutics
    Topic:
    Lymphoma therapies
    Date added:
    06/24/2022
    Date updated:
    09/19/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Notable Labs
    Topic:
    Clinical Trial design
    Date added:
    06/24/2022
    Date updated:
    09/19/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Novartis
    Topic:
    CAR T-cell therapy
    Date added:
    06/24/2022
    Date updated:
    09/19/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Genmab
    Topic:
    Bispecifics
    Date added:
    06/24/2022
    Date updated:
    09/19/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    AbbVie
    Topic:
    Lymphoma therapies
    Date added:
    06/24/2022
    Date updated:
    09/19/2024
Return to 2022 Cellular Therapy Conference – Translating recent evidence on cellular therapy to real world management of malignancies